Reviva Pharmaceuticals Holdings, Inc. announced on September 18, 2025, a registered public offering of 27 million shares and warrants for gross proceeds of $9.05 million, intending to use funds for R&D and working capital. This significant event is categorized under "Changes in capital structure" with a neutral sentiment.